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Abstract
Background
Sexually transmitted infections (STIs) including Chlamydia trachomatis (CT), Neisseria
gonorrhoeae (NG), Treponema pallidum (TP), and cytomegalovirus (CMV) may lead to
adverse pregnancy and infant outcomes. The role of combined maternal STIs in HIV
mother-to-child transmission (MTCT) was evaluated in mother-infant pairs from NICHD
HPTN 040.
Methodology
Urine samples from HIV-infected pregnant women during labor were tested by polymerase
chain reaction (PCR) for CT, NG, and CMV. Infant HIV infection was determined by serial
HIV DNA PCR testing. Maternal syphilis was tested by VDRL and confirmatory treponemal
antibodies.
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Results
A total of 899 mother-infant pairs were evaluated. Over 30% had at least one of the following
infections (TP, CT, NG, and/or CMV) detected at the time of delivery. High rates of TP
(8.7%), CT (17.8%), NG (4%), and CMV (6.3%) were observed. HIV MTCT was 9.1% (n =
82 infants). HIV MTCT was 12.5%, 10.3%, 11.1%, and 26.3% among infants born to women
with CT, TP, NG or CMV respectively. Forty-two percent of HIV-infected infants were born
to women with at least one of these 4 infections. Women with these infections were nearly
twice as likely to have an HIV-infected infant (aOR 1.9, 95% CI 1.1–3.0), particularly those
with 2 STIs (aOR 3.4, 95% CI 1.5–7.7). Individually, maternal CMV (aOR 4.4 1.5–13.0) and
infant congenital CMV (OR 4.1, 95% CI 2.2–7.8) but not other STIs (TP, CT, or NG) were
associated with an increased risk of HIV MTCT.
Conclusion
HIV-infected pregnant women identified during labor are at high risk for STIs. Co-infection
with STIs including CMV nearly doubles HIV MTCT risk. CMV infection appears to confer
the largest risk of HIV MTCT.
Trial registration
NCT00099359.
Introduction
Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Treponema pallidum (TP) con-
tribute to formidable global burden of treatable bacterial sexually transmitted infections (STIs)
with nearly a quarter of a billion of new cases reported annually.[1] These treatable STIs dis-
proportionately impact the health of pregnant women, particularly adolescents and young
women in low and middle-income countries.[1–3] Untreated CT, NG, and TP are associated
with adverse pregnancy outcomes including spontaneous abortion, stillbirth, preterm labor
and delivery. Maternal infection with these conditions has also been associated with neonatal
infections such as conjunctivitis (CT, NG), pneumonia (CT), and disseminated infection (TP,
NG); TP may be particularly devastating given its associations with multi-organ involvement,
failure to thrive, and neonatal death.[4–11] Apart from these bacterial STIs, other sexually
transmitted infections including viruses such as cytomegalovirus (CMV)[12, 13] are often
overlooked but can also have profound infant sequelae including neurodevelopmental anoma-
lies and sensorineural hearing loss when acquired in-utero.[14, 15] CMV, which can be trans-
mitted by close or sexual contact, is the major infectious etiology of sensorineural hearing loss
and developmental delay, and congenital infection globally may be as high as 1–5%.[16–18]
Routine antenatal screening for these conditions is not routine practice in many regions of the
world, particularly in low and middle-income countries. These practices may have particular
importance for high-risk groups such as HIV-infected pregnant women and their infants.
Given earlier findings of our HPTN 040 sub-studies evaluating the individual effects of
STIs on HIV MTCT (CT and NG and HIV MTCT; TP and HIV MTCT; and CMV and HIV
MTCT),[19–22] the following analysis provides a more comprehensive evaluation of the risk
factors associated with these STIs (CT, NG, TP, and CMV) and the impact of these combined
STIs (chlamydia, gonorrhea, syphilis, CMV) and HIV MTCT
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pregnant women who did not receive antiretroviral drugs (ARV) during pregnancy.
Methods
Study design
This study was a retrospective, cross-sectional clinical trial sub-study of the National Institute
of Child Health and Human Development (NICHD) HIV Prevention Trials Network (HPTN)
040 trial, which is also known as the International Maternal Pediatric Adolescent AIDS Clini-
cal Trials Network (IMPAACT) P1043. Clinical data and specimens were collected from
NICHD/HPTN 040 (P1043), a phase 3, triple-arm, randomized, open-label, multi-center
study aimed at the prevention of intrapartum HIV transmission to infants born to HIV-
infected pregnant women, who had not received antiretroviral drugs until labor and delivery
due to late diagnosis of infection.[23] Enrollment in the HPTN 040 parent study occurred
from April 2004 through July 2010 with the last patients followed until 2011, which included
1684 HIV-infected pregnant women, including the majority who were diagnosed as HIV-
infected at the time of labor and delivery. All mothers provided written informed consent.
Enrollment occurred at multiple sites in Brazil, South Africa, Argentina, and the United States.
Infants <32 weeks of age were excluded from the study. All HIV-exposed infants enrolled in
the study were formula-fed. Infants were randomized at birth to one of three neonatal prophy-
lactic ARV regimens. The primary endpoint was HIV infection status at 3 months of age.
Women were enrolled during labor and delivery with information obtained on maternal
sociodemographics, obstetric history including prior prenatal care, prior stillbirths, and risk
behaviors during pregnancy. Maternal plasma HIV RNA levels and T lymphocyte subsets
were collected. Syphilis testing was performed using Venereal Disease Research Laboratory
(VDRL) titers with confirmatory treponemal syphilis antibody tests performed, as per stan-
dard of care.[20] Infants were followed until 6 months of age for safety and toxicity monitoring
in the parent study with serious adverse events (SAEs) recorded as previously described.[23]
HIV diagnosis. HIV testing of infants occurred within 48 hours of birth, 14 days, 4–6
weeks, 3, and 6 months of age. Confirmatory HIV DNA testing was done for positive results.
Testing procedures have been previously described.[23]
Chlamydia, gonorrhea, and CMV testing. Stored maternal urine samples collected at the
time of labor and delivery or within 48 hours of giving birth were frozen and stored at study
sites. Aliquots (7 mL each) of stored frozen urine were shipped for testing at Cepheid, Sunny-
vale, CA. Urines were tested for the presence of CT and NG using the Xpert1 CT/NG assay.
Results were reported as positive, negative or indeterminate. Indeterminate test results were
repeated up to two times, and those that remained indeterminate were excluded from data
analysis. Remaining 1mL aliquots of maternal and infant urines (also collected within 48 hours
of delivery) were tested by qualitative Real-time PCR for CMV DNA (FOCUS Diagnostics
CMV Analyte Specific Reagent), and those with positive results were tested by quantitative
CMV PCR. In this study, given the limited number of maternal urines available for CMV PCR
testing, primarily infant CMV urine results were used in the analysis, (although analysis was
also done with maternal urine CMV PCR results when available as indicated in our Tables).
The STIs were not treated in pregnancy because the women had not presented for care, and
STI testing was done retrospectively on stored specimens.
Statistical analysis. All computations were done using SAS software v9.3 (Cary, NC,
USA). Two-sample t-test or Kruskal-Wallis test was used to compare mean or median differ-
ences for continuous variables as appropriate. Chi-squared or Fisher’s exact test was used to
compare differences of proportions for categorical variables. Univariate and multivariate
STIs (chlamydia, gonorrhea, syphilis, CMV) and HIV MTCT
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logistic regression modeling was used to examine the relationship of HIV MTCT and maternal
STI infection (CT, NG, TP, CMV) with potential risk factors respectively. The risk factors
include maternal demographic, alcohol, tobacco, illegal substance use, pregnancy and delivery
characteristics, and HIV-related clinical characteristics. Covariates with a p-value of 0.15 or
less from univariate models were selected for the initial multivariable model. Covariates with
an overall p-value <0.05 were retained in the final model.
Human subjects. The study was approved by the institutional review boards and national
ethics committees at each of the participating study sites. The study was approved by the OHRP,
the HPTN ethics board and the NICHD. It was also approved by the IRBs of the following institu-
tions locally: Fiocruz, Rio de Janeiro, Hospital dos Servidores do Estado, Rio de Janeiro, Hospital
Geral de Nova Iguacu, Rio de Janeiro, Grupo Hospitalar Conceicao in Porto Alegre (Hospital Con-
ceicao and Hospital Femina), Santa Casa da Misericordia, Porto Alegre, Universidade Federal de
Minas Gerais, Belo Horizonte, Universidade Federal de Sao Paulo, Sao Paulo and Ribeirao Preto,
all in Brazil; Foundation for Maternal and Infant Health, Buenos Aires, Argentina, SAMRC and
Perinatal HIV Research Unit, Soweto, South Africa, Tygerberg Hospital, Cape Town, South Africa,
Boston University School of Medicine, MA, USA. UCLA IRB #02-04-86-12 approved the NICHD
HPTN 040 study and was the lead IRB for the overall study. This particular study was a secondary
endpoint analysis of the parent study and evaluated previously collected data and specimens from
NICHD HPTN 040. As such, it received the UCLA IRB approval exemption number 14–001348.
Results
Baseline characteristics of mother-infant pairs
Among 1684 mother-infant pairs enrolled in the parent study, 899 pairs (53.4%) had specimens
available for maternal CT, NG, TP, and infant CMV testing. Specimen availability for testing of
all four potential co-infections determined inclusion in the present analysis. As such, 785
mother-infant pairs (approximately 47% of the original HPTN 040 cohort) were excluded. We
evaluated potential differences in both populations and determined that both groups were very
similar in most parameters (S1 Table). Most women in this analysis (86.2%) were from the Amer-
icas (Brazil, Argentina, and the U.S.) compared to South Africa (13.8%). (Table 1) The mean
maternal age was 26.5 (SD 6.3) years, and the majority received some prenatal care during preg-
nancy (69.4%). High rates of alcohol (36.5%), tobacco (37%), and illegal substance (9.8%) usage
were noted during pregnancy. There were also high rates of prior poor pregnancy outcomes
reported such as stillbirth (4.8%). Median log10 HIV plasma viral load at the time of delivery was
4.2 (interquartile range = IQR 1.7–6.5) copies/mL, with 58% having HIV viral load>10,000 cop-
ies/mL; the median CD4 count was 465 (IQR 12–2160) cells/mm3. Preterm delivery (<37 weeks)
occurred in 9.2% of infants, and 15.8% were of low birth weight (<2500 grams). Approximately
38.9% of infants experienced a serious adverse event (SAE) during the study period.
Rates of co-infections were high in this sub-cohort; over 30% of women had at least one of
the infections of interest (TP, CT, NG, and/or CMV). High rates of TP (8.7%), CT (17.8%),
and NG (4%) were found. Based on a positive infant urine CMV PCR at birth, which revealed
the presence of congenital CMV (cCMV) infection and was used as a surrogate for active
maternal CMV infection, 6.3% of women had CMV infection during pregnancy. (Table 1)
Characteristics of STI positive and STI negative HIV-infected pregnant
women
Characteristics of mother-infant pairs were compared for women with and without STIs (TP,
CT, NG, and/or CMV). (Table 2) Most women with STIs were under 30 years of age (77.3%).
STIs (chlamydia, gonorrhea, syphilis, CMV) and HIV MTCT
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Table 1. Demographic, Baseline, and other characteristics of NICHD HPTN 040 mother-infant pairs.
Total (N = 899) Mean
(std. dev.)
Median
(min-max)
n (col %)
Maternal CMV (CMV viruria)
Detected 23 (2.6)
Missing 647 (72.0)
Not detected 229 (25.5)
Parent HPTN 040 Study arm
ZDV 304 (33.8)
ZDV+NVP 307 (34.1)
ZDV+3TC+NFV 288 (32.0)
Maternal age (years) 26.5 (6.3) 26 (14–47)
13–24 376 (41.8)
25–29 252 (28.0)
30 and older 271 (30.1)
Maternal HIV viral load, categorical (copies/mL)
400 52 (5.8)
401 to 10,000 322 (35.8)
10,001 to 100,000 418 (46.5)
>100,000 104 (11.6)
Log10 maternal HIV viral load 4.1 (0.8) 4.2 (1.7–6.5)
Maternal CD4+ count (cells/mm3) 519.3 (308.8) 465 (12–2160)
Region
Americas 775 (86.2)
South Africa 124 (13.8)
Mode of delivery
Cesarean before rupture 246 (27.4)
Vaginal + CS after rupture 653 (72.6)
Maternal syphilis (TP)
No 821 (91.3)
Yes 78 (8.7)
Maternal chlamydia (CT) or gonorrhea (NG)
No 726 (80.8)
Yes 173 (19.2)
Maternal Chlamydia (CT)
No 739 (82.2)
Yes 160 (17.8)
Maternal Gonorrhea (NG)
No 863 (96.0)
Yes 36 (4.0)
CMV (Infant Congenital CMV; cCMV)
No 842 (93.7)
Yes 57 (6.3)
Any STI (maternal TP, CT, NG, or
cCMV positive)
No 626 (69.6)
Yes 273 (30.4)
Prenatal care
No 273 (30.4)
(Continued )
STIs (chlamydia, gonorrhea, syphilis, CMV) and HIV MTCT
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Rates of STIs (35.6%) were highest among young women (13–24 years). The results from the
adjusted multivariable model indicated that younger women were 1.6 to nearly two times
more likely to have an STI (aOR 1.9, 95% CI 1.3–2.8 for those 13–24 years of age and aOR 1.6,
Table 1. (Continued)
Total (N = 899) Mean
(std. dev.)
Median
(min-max)
n (col %)
Yes 624 (69.4)
Time (hours) of membrane rupture to delivery
Unknown 93 (10.3)
>24 25 (2.8)
12–24 42 (4.7)
6-<12 69 (7.7)
.5-<6 192 (21.4)
0.5 478 (53.2)
Alcohol use during pregnancy
1/week 139 (15.6)
>1/month, <1/week 64 (7.2)
1/month 123 (13.8)
Never 566 (63.5)
Illegal substance use during pregnancy
Yes 88 (9.8)
No 807 (90.2)
Infant death
No 879 (97.8)
Yes 20 (2.2)
Tobacco use during pregnancy
>10/day 124 (13.9)
6-10/day 63 (7.0)
5/day 144 (16.1)
Never 563 (63.0)
Gestation age (weeks) 38.6 (1.6) 39 (32–42)
36 or less (preterm) 83 (9.2)
37 or more 816 (90.8)
Low birth weight (grams) 3009.4 (516.7) 3010 (1595–4410)
 2500 757 (84.2)
< 2500 142 (15.8)
Prior Stillbirth
No 855 (95.2)
Yes 43 (4.8)
Any Infant Serious Adverse Event
No 549 (61.1)
Yes 350 (38.9)
Abbreviations: 3TC = lamivudine; CI, confidence interval; CMV, cytomegalovirus; cCMV = congenital CMV infection; CS = Cesarean section; CT =
Chlamydia trachomatis; HIV, human immunodeficiency virus; NFV = nelfinavir; NG = Neisseria gonorrhoeae; NVP = nevirapine; OR, odds ratio; SD,
standard deviation; STI = sexually transmitted infection; ZDV = zidovudine.
https://doi.org/10.1371/journal.pone.0189851.t001
STIs (chlamydia, gonorrhea, syphilis, CMV) and HIV MTCT
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Table 2. Correlates and outcomes associated with having Any Maternal STI [Syphilis (TP), chlamydia (CT), gonorrhea (NG) or CMV].
STI
Positive (N = 273)
STI Negative (N = 626) Unadjusted Adjusted
n (row %) n (row %) OR (95% CI) p-value OR (95% CI) p-value
Parent HPTN 040 Study arm
ZDV 91 (29.9) 213 (70.1) 1.00
ZDV+NVP 103 (33.6) 204 (66.4) 1.18 (0.84–1.66) 0.34
ZDV+3TC+NFV 79 (27.4) 209 (72.6) 0.88 (0.62–1.26) 0.50
Maternal age (years)
13–24 134 (35.6) 242 (64.4) 1.87 (1.31–2.66) 0.001 1.93 (1.34–2.78) 0.0004
25–29 77 (30.6) 175 (69.4) 1.48 (1.00–2.19) 0.05 1.63 (1.09–2.45) 0.02
30 and older 62 (22.9) 209 (77.1) 1.00 1.00
Region
Americas 237 (30.6) 538 (69.4) 1.00
South Africa 36 (29.0) 88 (71.0) 0.93 (0.61–1.41) 0.73
Maternal HIV viral load,
categorical (copies/mL)
400 13 (25.0) 39 (75.0) 1.00
401 to 10,000 91 (28.3) 231 (71.7) 1.18 (0.60–2.32) 0.63
10,001 to 100,000 131 (31.3) 287 (68.7) 1.37 (0.71–2.65) 0.35
>100,000 36 (34.6) 68 (65.4) 1.59 (0.75–3.35) 0.22
Log10 of maternal viral load 271 (30.2) 625 (69.8) 1.14 (0.96–1.36) 0.12
Maternal CD4+ count
(cells/mm3)/100
268 (30.3) 617 (69.7) 1.03 (0.98–1.08) 0.20
Mode of delivery
Cesarean before rupture 59 (24.0) 187 (76.0) 0.65 (0.46–0.91) 0.01 0.55 (0.37–0.83) 0.004
Vaginal + CS After rupture 214 (32.8) 439 (67.2) 1.00 1.00
Prenatal Care
No 95 (34.8) 178 (65.2) 1.00
Yes 178 (28.5) 446 (71.5) 0.75 (0.55–1.01) 0.06
Alcohol use during pregnancy
1/week 55 (39.6) 84 (60.4) 1.71 (1.16–2.51) 0.01
>1/month, <1/week 22 (34.4) 42 (65.6) 1.36 (0.79–2.36) 0.27
1/month 37 (30.1) 86 (69.9) 1.12 (0.73–1.72) 0.60
Never 157 (27.7) 409 (72.3) 1.00
Tobacco use during pregnancy
>10/day 45 (36.3) 79 (63.7) 1.53 (1.01–2.30) 0.04
6-10/day 20 (31.7) 43 (68.3) 1.25 (0.71–2.19) 0.44
5/day 53 (36.8) 91 (63.2) 1.56 (1.06–2.30) 0.02
Never 153 (27.2) 410 (72.8) 1.00
Illegal substance use
during pregnancy
Yes 36 (40.9) 52 (59.1) 1.68 (1.07–2.63) 0.03
No 236 (29.2) 571 (70.8) 1.00
Infant death
No 268 (30.5) 611 (69.5) 1.00
Yes 5 (25.0) 15 (75.0) 0.76 (0.27–2.11) 0.60
Gestation age (weeks)
36 or less 30 (36.1) 53 (63.9) 1.33 (0.83–2.14) 0.23
37 or more 243 (29.8) 573 (70.2) 1.00
(Continued )
STIs (chlamydia, gonorrhea, syphilis, CMV) and HIV MTCT
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95% CI 1.1–2.5 for those 25–29 years of age) when compared with older women ages 30 years
and above. Infants with any SAEs were 2.4-times more likely to born to mothers with STIs
(aOR 2.4, 95% CI: 1.8–3.2). Cesearean delivery prior to rupture of membranes was less fre-
quent in women with maternal STIs (aOR 0.55, 95% CI 0.37–0.83). (Table 2) In addition, fre-
quent alcohol use ( 1/week) (OR 1.7, 95% CI 1.2–2.5), frequent tobacco use (>10/day) (OR
1.5, 95% CI 1.0–2.3), and illegal substance use (OR 1.7, 95% CI 1.1–2.6) as well as low birth
weight infants (OR 1.5, 95% CI 1.0–2.2) were also associated with maternal STI-infection.
However, these risk factors were not significant in the adjusted multivariate models.
Syphilis, chlamydia, gonorrhea, CMV and HIV mother-to-child
transmission (MTCT)
82 infants of 899 (9.1%) HIV-infected mothers acquired HIV (in utero or intrapartum). Fifty
(61%) infants were HIV-infected in utero, while 32 (39%) were infected intrapartum. Thirty-
five (42.7%) HIV-infected infants were born to women with at least one of the STIs of interest
(TP, CT, NG and/or CMV), whereas maternal STI rates among HIV-uninfected infants were
29.1%. (Table 3) Of the 35 HIV-infected infants born to women with STIs, 11 (31.4%) were
born to women with multiple STIs, among whom in utero infection was the more common
means of infant HIV acquisition (73%). (S2 Table includes additional details of HIV in utero,
intrapartum transmission and specific maternal STIs). While HIV MTCT rates were higher
among women with individual TP, CT, and NG infections compared to women without these
STIs at delivery, this was not statistically significant: TP (10.3% vs 9%, p = 0.7), CT (12.5% vs
8.4%, p = 0.1), NG (11.1% vs 9%, p = 0.7). In contrast, HIV MTCT rates were significantly dif-
ferent in the presence of infant cCMV infection (i.e. congenital CMV infection), (26.3% vs 8%,
p<0.0001)] and maternal CMV infection [(i.e. maternal CMV viruria), (30.4% vs 8.3%,
p = 0.01)] compared to those without CMV. (Table 3) Infants born to women with one of
these STIs (CT, NG, TP, and/or CMV) were nearly twice as likely to be HIV-infected (OR 1.8,
95% CI 1.1–2.9) compared to those born to women without these infections; these findings
(aOR 1.9, 95% CI 1.1–3.0) persisted after adjusting for risk factors including maternal HIV
viral load, maternal HIV log10 viral load, maternal CD4 count, prolonged rupture of
Table 2. (Continued)
STI
Positive (N = 273)
STI Negative (N = 626) Unadjusted Adjusted
n (row %) n (row %) OR (95% CI) p-value OR (95% CI) p-value
Low birth weight (grams)
 2500 219 (28.9) 538 (71.1) 1.00
< 2500 54 (38.0) 88 (62.0) 1.51 (1.04–2.19) 0.03
History of prior stillbirth
No 261 (30.5) 594 (69.5) 1.00
Yes 12 (27.9) 31 (72.1) 0.88 (0.45–1.74) 0.7158
Any Infant Serious Adverse Event
No 128 (23.3) 421 (76.7) 1.00 1.00
Yes 145 (41.4) 205 (58.6) 2.33 (1.74–3.11) < .0001 2.38 (1.76–3.21) <0.0001
Abbreviations: 3TC = lamivudine; CI, confidence interval; CMV, cytomegalovirus; CS = Cesarean section; CT = Chlamydia trachomatis; HIV, human
immunodeficiency virus; NFV = nelfinavir; NG = Neisseria gonorrhoeae
NVP = nevirapine; OR, odds ratio; SD, standard deviation; STI = sexually transmitted infection; ZDV = zidovudine.
https://doi.org/10.1371/journal.pone.0189851.t002
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Table 3. Relationship of Infant HIV transmission with risk factors.
Infant HIV Positive
(N = 82)
Infant HIV Negative
(N = 817) Unadjusted Adjusted
n (row %) n (row %) OR (95% CI) p-value OR (95% CI) p-value
Maternal CMV
(CMV viruria)
Detected 7 (30.4) 16 (69.6) 4.84 (1.77–13.21) 0.002 4.44 (1.51–13.0) 0.01
Missing 56 (8.7) 591 (91.3) 1.05 (0.61–1.80) 0.87 0.96 (0.54–1.70) 0.89
Not detected 19 (8.3) 210 (91.7) 1.00 1.00
Parent HPTN 040 Study arm
ZDV 37 (12.2) 267 (87.8) 1.00 1.00
ZDV+NVP 22 (7.2) 285 (92.8) 0.56 (0.32–0.97) 0.04 0.52 (0.29–0.94) 0.03
ZDV+3TC+NFV 23 (8.0) 265 (92.0) 0.63 (0.36–1.08) 0.09 0.61 (0.34–1.09) 0.09
Maternal age (years)
13–24 36 (9.6) 340 (90.4) 0.96 (0.57–1.62) 0.87
25–29 19 (7.5) 233 (92.5) 0.74 (0.40–1.36) 0.33
30 and older 27 (10.0) 244 (90.0) 1.00
Maternal HIV viral load,
Categorical (copies/mL)
400 2 (3.8) 50 (96.2) 1.00
401 to 10,000 19 (5.9) 303 (94.1) 1.57 (0.35–6.94) 0.55
10,001 to 100,000 41 (9.8) 377 (90.2) 2.72 (0.64–11.59) 0.18
>100,000 20 (19.2) 84 (80.8) 5.95 (1.33–26.55) 0.02
Region
Americas 73 (9.4) 702 (90.6) 1.00
South Africa 9 (7.3) 115 (92.7) 0.75 (0.37–1.55) 0.44
Mode of delivery
Cesarean before rupture 19 (7.7) 227 (92.3) 0.78 (0.46–1.34) 0.37
Vaginal + CS after rupture 63 (9.6) 590 (90.4) 1.00
Maternal syphilis (TP)
No 74 (9.0) 747 (91.0) 1.00
Yes 8 (10.3) 70 (89.7) 1.15 (0.53–2.49) 0.72
Maternal chlamydia (CT) or gonorrhea (NG)
No 62 (8.5) 664 (91.5) 1.00
Yes 20 (11.6) 153 (88.4) 1.40 (0.82–2.39) 0.22
Maternal chlamydia (CT)
No 62 (8.4) 677 (91.6) 1.00
Yes 20 (12.5) 140 (87.5) 1.56 (0.91–2.67) 0.10
Maternal gonorrhea (NG)
No 78 (9.0) 785 (91.0) 1.00
Yes 4 (11.1) 32 (88.9) 1.26 (0.43–3.65) 0.67
CMV (Infant Congenital CMV; cCMV)
No 67 (8.0) 775 (92.0) 1.00
Yes 15 (26.3) 42 (73.7) 4.13 (2.18–7.84) < .0001
Any STI (maternal TP, CT, NG or cCMV positive)
No 47 (7.5) 579 (92.5) 1.00 1.00
Yes 35 (12.8) 238 (87.2) 1.81 (1.14–2.88) 0.01 1.85 (1.13–3.02) 0.01
Subjects with 0, 1, 2, 3, 4
STIs
0 STI 47 (7.5) 579 (92.5) 1.00
(Continued )
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membranes (either 12–24 hours or>24 hours), illegal substance use during pregnancy, and
infant death.
Detectable CMV from the urine of women and infants were important risk factors for
infant HIV acquisition. Women with CMV detected at the time of labor and delivery were
over four times more likely to have an HIV-infected infant than those without CMV viruria in
adjusted analyses (aOR 4.4, 95% CI 1.5–13.0). Similarly, women whose infants had CMV
detected in urine after birth (i.e. congenital CMV; cCMV) were more likely to also have infants
with HIV-infected than those without CMV viruria (i.e. without congenital CMV) in the
unadjusted analysis (OR 4.1, 95% CI 2.2–7.8), but this did not remain statistically significant in
adjusted analysis. (Table 3) Other factors associated with infant HIV acquisition included log10
HIV maternal viral load (aOR 1.9, 95% CI 1.4–2.5), illegal substance use during pregnancy
Table 3. (Continued)
Infant HIV Positive
(N = 82)
Infant HIV Negative
(N = 817) Unadjusted Adjusted
n (row %) n (row %) OR (95% CI) p-value OR (95% CI) p-value
1 STI 24 (10.8) 199 (89.2) 1.49 (0.89–2.49) 0.13 1.57 (0.91–2.71) 0.11
2 STIs 10 (23.8) 32 (76.2) 3.85 (1.78–8.31) 0.001 3.44 (1.53–7.74) 0.003
3 STIs 1 (12.5) 7 (87.5) 1.76 (0.21–14.61) 0.60 1.12 (0.13–10.1) 0.92
Prenatal Care
No 22 (8.1) 251 (91.9) 1.00
Yes 60 (9.6) 564 (90.4) 1.21 (0.73–2.02) 0.46
Time (hours) of membrane
Rupture prior to Delivery
Unknown 7 (7.5) 86 (92.5) 1.00 (0.43–2.32) 1.00
>24 5 (20.0) 20 (80.0) 3.07 (1.09–8.66) 0.03
12–24 8 (19.0) 34 (81.0) 2.89 (1.25–6.71) 0.01
6-<12 6 (8.7) 63 (91.3) 1.17 (0.47–2.89) 0.73
.5-<6 20 (10.4) 172 (89.6) 1.43 (0.80–2.54) 0.22
0.5 36 (7.5) 442 (92.5) 1.00
Alcohol use during pregnancy
> = 1/week 17 (12.2) 122 (87.8) 1.38 (0.77–2.47) 0.28
>1/month, <1/week 5 (7.8) 59 (92.2) 0.84 (0.32–2.18) 0.72
1/month 7 (5.7) 116 (94.3) 0.60 (0.26–1.35) 0.21
Never 52 (9.2) 514 (90.8) 1.00
Illegal substance use
during pregnancy
Yes 13 (14.8) 75 (85.2) 1.85 (0.98–3.51) 0.06 2.32 (1.16–4.64) 0.02
No 69 (8.6) 738 (91.4) 1.00 1.00
Infant death
No 73 (8.3) 806 (91.7) 1.00 1.00
Yes 9 (45.0) 11 (55.0) 9.04 (3.63–22.52) < .0001 7.14 (2.71–18.8) 0.0001
Maternal CD4+ count
(cells/mm3)/100 82 (9.3) 803 (90.7) 0.90 (0.82–0.98) 0.02
Log10 of maternal HIV viral load 82 (9.2) 814 (90.8) 1.88 (1.40–2.53) < .0001 1.85 (1.35–2.53) 0.0001
Abbreviations: 3TC = lamivudine; CI, confidence interval; CMV, cytomegalovirus; cCMV = congenital CMV infection CS = Cesarean section; CT =
Chlamydia trachomatis; HIV, human immunodeficiency virus; NFV = nelfinavir; NG = Neisseria gonorrhoeae; NVP = nevirapine; OR, odds ratio; SD,
standard deviation; STI = sexually transmitted infection; ZDV = zidovudine.
https://doi.org/10.1371/journal.pone.0189851.t003
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(aOR 2.3, 95% CI 1.2–4.6), and subsequent infant death (aOR 7.1, 95% CI 2.7–18.8), whereas
higher maternal CD4 count was protective (OR 0.90, 95% CI 0.82–0.98) in the unadjusted
analysis. (Table 3)
Further evaluation was done to compare the proportion of maternal STI infections (0 vs 1
vs 2 vs 3 STIs) between HIV-infected and HIV-uninfected infants. (Table 4) Of the 35 HIV-
infected infants born to women with STIs (CT, NG, TP, and/or CMV), the majority were
those born to women with one STI (n = 24, 68.6%) as opposed to two (n = 10, 28.6%) or three
STIs (n = 1, 2.9%). However, significant differences were noted in the proportion of maternal
STI infections (0 vs 1, 2 or 3 STIs) and infant HIV-infection, which ranged from 7.5% (47/626)
for 0 STIs to 23.8% (10/42) for 2 STIs. Additional regression analyses were done to elucidate
these relationships between the number of STIs and HIV MTCT. Women with two STIs were
3.4 times more likely to transmit HIV to their infants than those without STIs (aOR 3.4, 95%
CI 1.5–7.7). (Table 3)
Discussion
The results of this study were notable for the high prevalence of overall STIs (TP, CT, NG, and
CMV) in this sub-cohort of HIV-infected pregnant women. The presence of at least one of
these STIs represented an increased risk for HIV MTCT, particularly two STIs, with CMV
being the most important co-infection contributing to HIV perinatal transmission.
Table 4. Number of maternal STIs (chlamydia, gonorrhea, syphilis, CMV) Frequency distribution by infant HIV-infection status.
Infant HIV-infected
(N = 82)
Infant
HIV-uninfected (N = 817)
p-value* (for total only)
n (col %) n (col %) n (col %)
0.003
0 STI (n = 626) 47 (57.3) 579 (70.9)
1 STI (n = 223)
TP 6 (7.3) 50 (6.1)
CT 9 (12) 109 (13.3)
NG 11 (1.4)
CMV 9 (11) 29 (3.6)
Total 24 (29.3) 199 (24.4)
2 STIs (n = 42)
CT, NG 3 (3.7) 13 (1.6)
CT, TP 2 (2.4) 8 (1.0)
CT, CMV 5 (6.1) 3 (1.3)
NG, TP 2 (0.2)
TP, CMV 6 (0.7)
Total 10 (12.2) 32 (3.9)
3 STIs (n = 8)
CT, TP, CMV 1 (0.1)
CT, NG, CMV 1 (1.2) 3 (0.4)
CT, NG, TP 3 (0.4)
Total 1 (1.2) 7 (0.9)
* P-value was generated by the Chi-square test to compare the proportion of STI infections (0 STI vs 1 STI vs 2 STIs vs 3 STIs) between HIV-infected and
HIV-uninfected infants.
Abbreviations: CMV, cytomegalovirus and specifically refers to infant congenital CMV here; CT = Chlamydia trachomatis; HIV, human immunodeficiency
virus; NG = Neisseria gonorrhoeae; STI = sexually transmitted infection; TP = Treponema pallidum (syphilis).
https://doi.org/10.1371/journal.pone.0189851.t004
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In general, limited published studies have focused on evaluating the impact of untreated
maternal STIs such as CT, NG, TP, and active CMV infection in pregnancy on HIV mother-
to-child transmission (MTCT), nor have they comparatively evaluated the potential contribu-
tion of individual co-infections within the same cohort on perinatal HIV transmission. The
biological plausibility for STIs increasing HIV MTCT risk was suggested in studies of non-
pregnant women which demonstrated increased HIV genital shedding in the presence of STIs.
[24, 25] Chorioamnionitis has also been demonstrated to increase the risk of HIV MTCT.[26–
33] Selected studies have demonstrated a link between specific STIs with HIV MTCT, includ-
ing results from our prior individual HPTN 040 analyses.[19–22, 34–37]
Over 30% of HIV-infected pregnant women in the present analysis had at least one STI
(TP, CT, NG, and/or CMV). Our findings re-emphasize that women in our study were at
high-risk for multiple STIs apart from HIV, particularly younger women. Predictors of STIs
such as younger maternal age has been previously well-documented.[38–43] Women enrolled
in the parent study were a high-risk group by definition; they were late to present for HIV
diagnosis and not on antiretrovirals (ARVs) during pregnancy because they were only diag-
nosed with HIV at the time of labor and delivery. Nearly 30% did not receive antenatal care
and more than a third of women engaged in tobacco, alcohol, and/or illegal substance use dur-
ing pregnancy.
Collectively, results of this analysis provide additional support that STIs (TP, CT, NG, and/
or CMV) increase the risk of HIV MTCT by nearly two-fold and for those with two STIs, possi-
bly more than three-fold. Forty-three percent of infants with HIV were born to women with at
least one of these STIs, while rates of HIV MTCT were most pronounced in women with CMV
(>26% but possibly as high as>30% for those with CMV viruria) and CT (12.5%) infection.
Our previous studies of individual STIs also demonstrated that these conditions were asso-
ciated with an increased risk of HIV MTCT. In our earlier individual analyses, 10% of the orig-
inal NICHD HPTN 040 maternal cohort had positive syphilis results and were twice as likely
to transmit HIV to their infants (adjusted OR 2.1, 95% CI 1.3–1.4).[20] Among 1373 HIV-
infected pregnant women with high rates of CT (18.1%) and NG (4.6%), CT appeared to pose
a possible 1.5-fold increased risk of HIV MTCT (OR 1.5, 95% CI 0.94–2.3).[19] We believe
that the present study did not highlight this MTCT risk as clearly due to the reduction in sam-
ple size required to perform a combined analysis, which included testing of subjects for all four
co-infections. Apart from our own published results from HPTN 040, literature focusing on
the impact of STIs (TP, CT, and NG) and the risk of HIV MTCT has also demonstrated mixed
results, particularly for CT and NG.[33, 34, 36, 40]
In the present study, maternal CMV (especially CMV viruria) was significantly associated
with an increased risk of HIV MTCT (more than four-fold). A prior analysis of the same
cohort demonstrated high rates of CMV viruria (9.2%) among HIV-infected pregnant women
at the time of delivery, with maternal CMV viruria being associated with a similar but higher
risk of HIV MTCT (aOR 5.6, 95% CI 1.9–16.8).[22] The clinical significance of detectable
CMV viruria at the time of labor and delivery in HIV-infected pregnant women not on ARVs,
however, is not well-understood. Considering that it is very likely that most of the studied
women were already CMV seropositive before pregnancy due to the frequent exposure to
CMV in these populations, CMV viruria might result from CMV reactivation in the genitouri-
nary tract or reinfection with a new virus strain.[44]
The relationship between HIV and CMV perinatal infections is complex, since infection
with one may be a risk factor for infection with the other pathogen. Yet, while several studies
have shown that HIV-exposure in pregnancy is a risk factor for congenital CMV, fewer have
demonstrated that congenital CMV acquisition is also a risk factor for HIV perinatal transmis-
sion.[31, 37, 45, 46] To our knowledge, the only other primary study to address this aspect of
STIs (chlamydia, gonorrhea, syphilis, CMV) and HIV MTCT
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the relationship was a retrospective case-control study of 293 HIV-infected and HIV-exposed,
uninfected infants from Thailand.[37, 47] They found that congenital CMV was a risk factor
for HIV MTCT, particularly for in utero HIV (OR 8.1, 95% CI 1.5–63.7).[37]
In summary, maternal co-infections such as TP, CT, NG, and CMV facilitate HIV perinatal
transmission by a variety of means. Genital tract infections from these organisms may lead to
cervicitis, which may trigger increased cervico-vaginal HIV viral shedding [24, 25, 48–52] or
may cause acute or chronic placental inflammation. [26, 30–34] This inflammation at the
maternal-fetal interface may induce immune activation and alter cytokine production, increas-
ing viral load, and upregulating the expression of CCR5 T-cell receptors as well as CCR5 HIV
co-receptors on Hofbauer cells (macrophages) in the placenta, which contribute towards
increased HIV tropism and infectivity.[46, 53] It has been suggested that many of these factors
are especially important in understanding the role CMV infection plays as a risk factor for
HIV MTCT, particularly at the placental interface. These pathogens appear to effectively over-
come inherent placental antiviral mechanisms that safeguard against fetal infection.[46, 53]
Study limitations
As discussed previously in our results section, specimen availability for testing for potential co-
infections determined inclusion in the present analysis. While study inclusion and exclusion
populations were similar, some differences were noted in maternal age, mode of delivery, prena-
tal care, alcohol use, tobacco use, and maternal HIV viral load. In addition, in the parent study,
28% of subjects came from South Africa and 72% from the Americas. This proportion was not
maintained in the sub-analysis as specimen availability was limited for South African subjects.
Therefore, 13.8% of subjects were from South Africa and the remainder from the Americas in
the present analysis, p< 0.0001. This implies that our results might not be as generalizable to
the South African site. Additional limitations include inability to test for other STIs and genital
tract infections such as bacterial vaginosis, Trichomonas vaginalis, and Herpes simplex virus.
Conclusion
We conducted this analysis to explore the potential synergy between several co-infections and
increased risk for HIV MTCT in a large cohort of HIV-infected mothers and HIV-exposed
infants. HIV-infected pregnant women in this cohort were at very high risk for STIs (TP, CT,
NG, and/or CMV). The presence of one or more infections nearly doubled the odds of HIV
MTCT, and the presence of two co-infections tripled the odds. In particular, CMV in HIV-
infected pregnant women, especially the presence of maternal CMV viruria at delivery,
appeared to confer the largest risk of perinatal HIV transmission. Our study’s results empha-
size the importance that undiagnosed STIs may play in pregnancy as risk factors for HIV
MTCT. Our data underscores the need to augment current existing antenatal care programs to
include STI screening, particularly for high-risk women such as young, HIV-infected pregnant
women as well as ensuring that HIV-infected women have consistent access to antiretroviral
treatment and monitoring, particularly during pregnancy.
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